Genomic insights into WNT/β-catenin signaling

Joseph Rosenbluh, Xiaoxing Wang, William C. Hahn

Research output: Contribution to journalReview ArticleOtherpeer-review

68 Citations (Scopus)

Abstract

The canonical WNT pathway regulates the stability of the proto-oncogene β-catenin and is aberrantly activated in many cancer types. Studies in a wide range of experimental models confirm that β-catenin activity is required for tumor initiation in cancers where this pathway is deregulated. However, to date this pathway has proven to be challenging to target therapeutically. Moreover, several lines of evidence suggest that other components and regulators of β-catenin exist. Here we will describe recent structural and functional studies describing genomic alterations and new regulators of β-catenin that lead to aberrant activation of the WNT/β-catenin pathway. These findings provide new insights into the biology of WNT/β-catenin signaling and suggest potential therapeutic opportunities.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalTrends in Pharmacological Sciences
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2014
Externally publishedYes

Keywords

  • β-catenin
  • cancer
  • synthetic lethality
  • WNT
  • YAP1

Cite this

Rosenbluh, Joseph ; Wang, Xiaoxing ; Hahn, William C. / Genomic insights into WNT/β-catenin signaling. In: Trends in Pharmacological Sciences. 2014 ; Vol. 35, No. 2. pp. 103-109.
@article{321b3461022b4030af8f078b9f7e8336,
title = "Genomic insights into WNT/β-catenin signaling",
abstract = "The canonical WNT pathway regulates the stability of the proto-oncogene β-catenin and is aberrantly activated in many cancer types. Studies in a wide range of experimental models confirm that β-catenin activity is required for tumor initiation in cancers where this pathway is deregulated. However, to date this pathway has proven to be challenging to target therapeutically. Moreover, several lines of evidence suggest that other components and regulators of β-catenin exist. Here we will describe recent structural and functional studies describing genomic alterations and new regulators of β-catenin that lead to aberrant activation of the WNT/β-catenin pathway. These findings provide new insights into the biology of WNT/β-catenin signaling and suggest potential therapeutic opportunities.",
keywords = "β-catenin, cancer, synthetic lethality, WNT, YAP1",
author = "Joseph Rosenbluh and Xiaoxing Wang and Hahn, {William C.}",
year = "2014",
month = "2",
doi = "10.1016/j.tips.2013.11.007",
language = "English",
volume = "35",
pages = "103--109",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier",
number = "2",

}

Genomic insights into WNT/β-catenin signaling. / Rosenbluh, Joseph; Wang, Xiaoxing; Hahn, William C.

In: Trends in Pharmacological Sciences, Vol. 35, No. 2, 02.2014, p. 103-109.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Genomic insights into WNT/β-catenin signaling

AU - Rosenbluh, Joseph

AU - Wang, Xiaoxing

AU - Hahn, William C.

PY - 2014/2

Y1 - 2014/2

N2 - The canonical WNT pathway regulates the stability of the proto-oncogene β-catenin and is aberrantly activated in many cancer types. Studies in a wide range of experimental models confirm that β-catenin activity is required for tumor initiation in cancers where this pathway is deregulated. However, to date this pathway has proven to be challenging to target therapeutically. Moreover, several lines of evidence suggest that other components and regulators of β-catenin exist. Here we will describe recent structural and functional studies describing genomic alterations and new regulators of β-catenin that lead to aberrant activation of the WNT/β-catenin pathway. These findings provide new insights into the biology of WNT/β-catenin signaling and suggest potential therapeutic opportunities.

AB - The canonical WNT pathway regulates the stability of the proto-oncogene β-catenin and is aberrantly activated in many cancer types. Studies in a wide range of experimental models confirm that β-catenin activity is required for tumor initiation in cancers where this pathway is deregulated. However, to date this pathway has proven to be challenging to target therapeutically. Moreover, several lines of evidence suggest that other components and regulators of β-catenin exist. Here we will describe recent structural and functional studies describing genomic alterations and new regulators of β-catenin that lead to aberrant activation of the WNT/β-catenin pathway. These findings provide new insights into the biology of WNT/β-catenin signaling and suggest potential therapeutic opportunities.

KW - β-catenin

KW - cancer

KW - synthetic lethality

KW - WNT

KW - YAP1

UR - http://www.scopus.com/inward/record.url?scp=84895075256&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2013.11.007

DO - 10.1016/j.tips.2013.11.007

M3 - Review Article

VL - 35

SP - 103

EP - 109

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 2

ER -